Q: What is Wezlana used for?

Wezlana is used to treat plaque psoriasis , psoriatic arthritis , Crohn's disease , and others.

Q: How does Wezlana work?

Targeting Inflammation Wezlana is a monoclonal antibody, which is a type of protein designed to recognize and bind to specific targets in the body. It specifically targets two naturally occurring proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23). Interrupting the Immune Response In people with certain autoimmune conditions, the body produces too much IL-12 and IL-23. These proteins act as messengers that tell the immune system to trigger inflammation. This process can lead to various symptoms, such as: The rapid overgrowth of skin cells in plaque psoriasis. Joint swelling and pain in psoriatic arthritis. Inflammation and damage in the digestive tract in Crohn’s disease and ulcerative colitis. Wezlana works by binding to these proteins before they can attach to immune cells. When the proteins are blocked, they cannot deliver the signals that cause inflammation. By interrupting this pathway, Wezlana helps to calm the overactive immune response and reduce the symptoms associated with these chronic inflammatory conditions.

Q: What are the active ingredients in Wezlana?

The active ingredient in Wezlana is ustekinumab .

Q: What drug class is Wezlana?

Wezlana belongs to the HIV-1 capsid inhibitor drug class.

Q: What is the dosage of Wezlana and how do I take it?

Administration Methods Wezlana is given by subcutaneous injection (under the skin) or by intravenous infusion (into a vein). The method of administration depends on the medical condition and whether it is the initial dose or a maintenance dose. For certain conditions, such as Crohn's disease or ulcerative colitis, the first dose is administered by a healthcare professional through a vein in a clinical setting. Follow-up doses for these conditions, and all doses for plaque psoriasis or psoriatic arthritis, are typically given as injections under the skin. Self-Injection Instructions If your healthcare provider determines it is appropriate, you or a caregiver may be trained to perform subcutaneous injections at home using a prefilled syringe. General steps for home administration include: Remove the medication from the refrigerator and allow it to reach room temperature before use. Do not shake the syringe. Choose an injection site such as the abdomen, thighs, buttocks, or upper arms. Avoid the area immediately around the belly button. Rotate the injection site with each dose. Do not inject into skin that is red, bruised, tender, or scarred. Missed Doses If you miss a dose, contact your healthcare provider immediately to determine when to schedule your next dose. Do not take extra medication or double the dose to make up for a missed one.

Q: Is Wezlana safe during pregnancy and breastfeeding?

Pregnancy Limited data are available regarding the use of Wezlana in pregnant women. Because Wezlana is a monoclonal antibody, it can cross the placenta and reach the developing fetus, especially during the second and third trimesters. Research has not established a clear link between the medication and an increased risk of major birth defects or pregnancy loss, but the evidence is not yet conclusive. Individuals who are pregnant or planning to become pregnant should discuss their treatment plan with a healthcare provider. A clinician can help weigh the benefits of managing the underlying condition against any potential risks to the pregnancy. Breastfeeding Small amounts of ustekinumab, the active ingredient in Wezlana, have been found in human breast milk. It is currently unknown if the medication is absorbed by the nursing infant or if it has any impact on milk production. The decision to breastfeed while using Wezlana involves considering the following factors: The health and developmental benefits of breastfeeding for the baby. The mother's clinical need for the medication to treat her condition. Any potential adverse effects on the breastfed child from the medication or the mother's condition. Consult a healthcare professional to determine the most appropriate approach for your specific situation.

Q: What is the FDA approval status of Wezlana?

FDA Approval and Interchangeability The U.S. Food and Drug Administration (FDA) approved Wezlana (ustekinumab-auub) in October 2023. It is designated as an interchangeable biosimilar to its reference product, Stelara. This status means that, depending on state pharmacy laws, Wezlana may be substituted for the reference product by a pharmacist without requiring a new prescription from the healthcare provider who wrote the original order. Approved Indications Wezlana is approved for use in the following patient populations and conditions: Plaque Psoriasis: For adults and pediatric patients 6 years of age and older with moderate to severe disease who are candidates for phototherapy or systemic therapy. Psoriatic Arthritis: For adults and pediatric patients 6 years of age and older with active disease. Crohn's Disease: For adults with moderately to severely active disease. Ulcerative Colitis: For adults with moderately to severely active disease. Regulatory Safety Information The FDA approval was based on a comprehensive review of evidence showing that Wezlana is highly similar to its reference product, with no clinically meaningful differences in safety, purity, or potency. While the medication does not have a Boxed Warning, the FDA-approved labeling includes warnings regarding the potential for serious infections and malignancies. There is currently no Risk Evaluation and Mitigation Strategy (REMS) required for this medication.

Question 1

What is Wezlana?

Accepted Answer

Wezlana is a monoclonal antibody that belongs to a class of medications known as interleukin antagonists. It works by binding to and blocking the activity of specific proteins in the body that are involved in the inflammatory response.

By interfering with these proteins, the medication helps to reduce inflammation and manage symptoms associated with certain chronic conditions. It is a biological product designed to target specific pathways within the immune system.

Question 2

What is Wezlana used for?

Accepted Answer

Wezlana is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and others.

Question 3

How does Wezlana work?

Accepted Answer

Targeting Inflammation

Wezlana is a monoclonal antibody, which is a type of protein designed to recognize and bind to specific targets in the body. It specifically targets two naturally occurring proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23).

Interrupting the Immune Response

In people with certain autoimmune conditions, the body produces too much IL-12 and IL-23. These proteins act as messengers that tell the immune system to trigger inflammation. This process can lead to various symptoms, such as:

The rapid overgrowth of skin cells in plaque psoriasis.
Joint swelling and pain in psoriatic arthritis.
Inflammation and damage in the digestive tract in Crohn’s disease and ulcerative colitis.

Wezlana works by binding to these proteins before they can attach to immune cells. When the proteins are blocked, they cannot deliver the signals that cause inflammation. By interrupting this pathway, Wezlana helps to calm the overactive immune response and reduce the symptoms associated with these chronic inflammatory conditions.

Question 4

What are the active ingredients in Wezlana?

Accepted Answer

The active ingredient in Wezlana is ustekinumab.

Question 5

What are the side effects of Wezlana?

Accepted Answer

The most common side effects reported with Wezlana include:

Upper respiratory infections, such as the common cold or sore throat
Headache
Fatigue or feeling tired
Injection site reactions, including pain, swelling, or redness
Diarrhea, nausea, or vomiting
Itching
Back pain or joint pain

While less common, Wezlana can cause serious side effects that require immediate medical attention. These include:

Serious Infections: Because Wezlana affects the immune system, it may increase the risk of serious bacterial, fungal, or viral infections, including tuberculosis (TB).
Allergic Reactions: Severe allergic reactions can occur. Seek emergency help if you experience hives, swelling of the face or throat, or difficulty breathing.
Posterior Reversible Encephalopathy Syndrome (PRES): This is a rare brain condition. Symptoms include headache, seizures, confusion, or vision changes.
Skin Cancer: Some patients may have an increased risk of certain types of non-melanoma skin cancer.
Lung Problems: In rare cases, lung inflammation can occur. Contact your doctor if you develop a new or worsening cough or shortness of breath.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Wezlana?

Accepted Answer

Wezlana belongs to the HIV-1 capsid inhibitor drug class.

Question 7

What is the dosage of Wezlana and how do I take it?

Accepted Answer

Administration Methods

Wezlana is given by subcutaneous injection (under the skin) or by intravenous infusion (into a vein). The method of administration depends on the medical condition and whether it is the initial dose or a maintenance dose.

For certain conditions, such as Crohn's disease or ulcerative colitis, the first dose is administered by a healthcare professional through a vein in a clinical setting.
Follow-up doses for these conditions, and all doses for plaque psoriasis or psoriatic arthritis, are typically given as injections under the skin.

Self-Injection Instructions

If your healthcare provider determines it is appropriate, you or a caregiver may be trained to perform subcutaneous injections at home using a prefilled syringe. General steps for home administration include:

Remove the medication from the refrigerator and allow it to reach room temperature before use.
Do not shake the syringe.
Choose an injection site such as the abdomen, thighs, buttocks, or upper arms. Avoid the area immediately around the belly button.
Rotate the injection site with each dose. Do not inject into skin that is red, bruised, tender, or scarred.

Missed Doses

If you miss a dose, contact your healthcare provider immediately to determine when to schedule your next dose. Do not take extra medication or double the dose to make up for a missed one.

Question 8

Is Wezlana safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Limited data are available regarding the use of Wezlana in pregnant women. Because Wezlana is a monoclonal antibody, it can cross the placenta and reach the developing fetus, especially during the second and third trimesters. Research has not established a clear link between the medication and an increased risk of major birth defects or pregnancy loss, but the evidence is not yet conclusive.

Individuals who are pregnant or planning to become pregnant should discuss their treatment plan with a healthcare provider. A clinician can help weigh the benefits of managing the underlying condition against any potential risks to the pregnancy.

Breastfeeding

Small amounts of ustekinumab, the active ingredient in Wezlana, have been found in human breast milk. It is currently unknown if the medication is absorbed by the nursing infant or if it has any impact on milk production.

The decision to breastfeed while using Wezlana involves considering the following factors:

The health and developmental benefits of breastfeeding for the baby.
The mother's clinical need for the medication to treat her condition.
Any potential adverse effects on the breastfed child from the medication or the mother's condition.

Consult a healthcare professional to determine the most appropriate approach for your specific situation.

Question 9

What forms and strengths does Wezlana come in?

Accepted Answer

Wezlana is supplied in the following forms for administration:

Subcutaneous Injection: This form is available in single-dose prefilled syringes and single-dose vials for injection under the skin.
Intravenous Infusion: This form is available as a solution in a single-dose vial. It is intended for dilution and administration through a vein by a healthcare professional.

Question 10

What is the FDA approval status of Wezlana?

Accepted Answer

FDA Approval and Interchangeability

The U.S. Food and Drug Administration (FDA) approved Wezlana (ustekinumab-auub) in October 2023. It is designated as an interchangeable biosimilar to its reference product, Stelara. This status means that, depending on state pharmacy laws, Wezlana may be substituted for the reference product by a pharmacist without requiring a new prescription from the healthcare provider who wrote the original order.

Approved Indications

Wezlana is approved for use in the following patient populations and conditions:

Plaque Psoriasis: For adults and pediatric patients 6 years of age and older with moderate to severe disease who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis: For adults and pediatric patients 6 years of age and older with active disease.
Crohn's Disease: For adults with moderately to severely active disease.
Ulcerative Colitis: For adults with moderately to severely active disease.

Regulatory Safety Information

The FDA approval was based on a comprehensive review of evidence showing that Wezlana is highly similar to its reference product, with no clinically meaningful differences in safety, purity, or potency. While the medication does not have a Boxed Warning, the FDA-approved labeling includes warnings regarding the potential for serious infections and malignancies. There is currently no Risk Evaluation and Mitigation Strategy (REMS) required for this medication.

Question 11

What should I know about Wezlana and withdrawal?

Accepted Answer

Discontinuation of Wezlana

Wezlana is a biologic medication and is not considered to be habit-forming or addictive. There are no documented reports of physical withdrawal syndromes occurring when the medication is stopped. Unlike some other classes of drugs, it does not typically require a tapering schedule where the dose is slowly reduced over time.

Return of Symptoms

The main risk of stopping Wezlana is the return of the underlying chronic condition. Because the medication works by suppressing specific parts of the immune system to control inflammation, stopping treatment allows that inflammation to return. This may lead to a relapse of symptoms, such as:

New or worsening skin plaques and redness in patients with psoriasis.
Increased joint pain, stiffness, and swelling in patients with psoriatic arthritis.
A return of abdominal pain, diarrhea, or rectal bleeding in patients with Crohn's disease or ulcerative colitis.

It is important to continue using the medication exactly as prescribed by your healthcare provider. Do not stop treatment or change your dosing schedule without medical consultation, as your doctor will need to monitor your condition and discuss alternative management options.

Wezlana

📋Overview

How It Works

Uses

Active Ingredients

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Wezlana

Hospitals.net Disclosure